Tammy O. Utset
About
In The Last Decade
Tammy O. Utset
43 papers receiving 3.2k citations
Hit Papers
Peers
Comparison fields: 5 of 100
- Rheumatology 2.3k
- Immunology 1.9k
- Radiology, Nuclear Medicine and Imaging 722
- Oncology 381
- Nephrology 375
Countries citing papers authored by Tammy O. Utset
This map shows the geographic impact of Tammy O. Utset's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tammy O. Utset with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tammy O. Utset more than expected).
Fields of papers citing papers by Tammy O. Utset
This network shows the impact of papers produced by Tammy O. Utset. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tammy O. Utset. The network helps show where Tammy O. Utset may publish in the future.
Co-authorship network of co-authors of Tammy O. Utset
This figure shows the co-authorship network connecting the top 25 collaborators of Tammy O. Utset. A scholar is included among the top collaborators of Tammy O. Utset based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tammy O. Utset. Tammy O. Utset is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 24 | |
| 2 | 49 | |
| 3 | 16 | |
| 4 | 59 | |
| 5 | 32 | |
| 6 | 11 | |
| 7 | 66 | |
| 8 | 23 | |
| 9 | 211 | |
| 10 | 19 | |
| 11 | 200 | |
| 12 | 121 | |
| 13 | 261 | |
| 14 | 78 | |
| 15 | Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial breakdown → | 972 |
| 16 | 1 | |
| 17 | 58 | |
| 18 | Prevalence of neurocognitive dysfunction and other clinical manifestations in disabled patients with systemic lupus erythematosus. | 46 |
| 19 | 9 | |
| 20 | Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. | 98 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.